CARDIOFLOW-B (02160) declined nearly 7% ahead of its earnings announcement. As of press time, the stock was down 4.2% to HK$1.37, with trading volume reaching HK$113.101 million. On the news front, CARDIOFLOW-B plans to convene a board meeting on August 28 to approve its interim results.

The company previously issued a profit warning, expecting net losses for the first half of 2025 to not exceed RMB 10 million, representing a year-on-year decrease of at least 83%. According to the announcement, the reduction in net losses is primarily attributed to several factors: the VitaFlow Liberty transcatheter aortic valve and retrievable delivery system has achieved sales in over 20 overseas countries and regions, with overseas revenue increasing more than twofold; the AnchorMan left atrial appendage closure system and its guiding system have made steady commercial progress in China and obtained CE marking for commercialization in Europe, collectively contributing to revenue growth; continued optimization of resource allocation and other measures have further enhanced operational efficiency; and the associated company 4C Medical completed Series D financing, with the group's reduced shareholding generating deemed disposal gains.